



Genmab Announces Appointment of Marisol Peron as Head of Communications and Investor Relations

March 11, 2019

Media Release

Copenhagen, Denmark, March 11, 2019

Genmab A/S (Nasdaq Copenhagen: GEN) announced today that Marisol Peron has been appointed Corporate Vice President, Communications and Investor Relations, effective March 11, 2019. Ms. Peron will be responsible for the strategic management of both internal and external communications and investor relations efforts for Genmab. Andrew Carlsen, who recently joined the company as Senior Director Investor Relations, continues to be the contact point for investors and analysts.

Ms. Peron joins Genmab with over 20 years' experience in corporate communications in the life sciences industry. She brings with her expertise in the creation, implementation and management of both internal and external corporate communications strategies, having previously spent 17 years at Sanofi, where she led communications for the vaccines division in North America and held various communications roles for Sanofi's oncology, cardiovascular and diabetes business units. Most recently, Ms. Peron served as the Vice President of Communications for North America at Ipsen Biopharmaceuticals.

Ms. Peron replaces Rachel Curtis Gravesen, who will pursue new opportunities elsewhere, but will be available during a short transition period.

"We are very pleased to add Marisol to strengthen our global leadership team and look forward to applying her expertise as she directs our communications efforts during this exciting period of growth at Genmab," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "We would also like to thank Rachel for her many years of excellent service to the company, and we wish Rachel the very best in her future endeavors."

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX[®] (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra[®] (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody[®] platform for generation of bispecific antibodies, the HexaBody[®] platform, which creates effector function enhanced antibodies and the HexElect[™] platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:

Andrew Carlsen, Senior Director, Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab[®]; the Y-shaped Genmab logo[®]; Genmab in combination with the Y-shaped Genmab logo[®]; HuMax[®]; DuoBody[®]; DuoBody in combination with the DuoBody logo[®]; HexaBody[®]; HexaBody in combination with the HexaBody logo[®]; DuoHexaBody[™]; HexElect[™]; and UniBody[®]. Arzerra[®] is a trademark of Novartis AG or its affiliates. DARZALEX[®] is a trademark of Janssen Pharmaceutica NV.

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark

Attachment

- [i03_190311_MR_New IR comms head](#)